Clinical Trial Detail

NCT ID NCT02953860
Title Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Anthony Elias
Indications

Her2-receptor negative breast cancer

Therapies

Enzalutamide + Fulvestrant

Age Groups: senior adult

Additional content available in CKB BOOST